Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis
Background: Novel treatments for osteoarthritis (OA) are needed for patients not responding to and/or not tolerating conventional treatments. In this prospective study the usefulness of Anakinra (Kineret) in the treatment of OA was evaluated. Methods: Eleven patients with symptomatic OA were treated...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2017;volume=12;issue=1;spage=17;epage=22;aulast=Scoville |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832543403650318336 |
|---|---|
| author | Craig Davis Scoville John Partridge Dickson |
| author_facet | Craig Davis Scoville John Partridge Dickson |
| author_sort | Craig Davis Scoville |
| collection | DOAJ |
| description | Background: Novel treatments for osteoarthritis (OA) are needed for patients not responding to and/or not tolerating conventional treatments. In this prospective study the usefulness of Anakinra (Kineret) in the treatment of OA was evaluated.
Methods: Eleven patients with symptomatic OA were treated with Anakinra (Kineret) over a 2–3 month period. Efficacy of response was determined if patients showed >30% improvement in the Western Ontario and McMaster Universities Osteoarthritis Index and/or Australian/Canadian Osteoarthritis Hand Index scoring with treatment. Nine of the 11 patients received Kineret intra-articular (IA) injections and 2/11 patients with erosive polyosteoarthritis received Kineret 100 mg subcutaneous injections daily for 30 days.
Results: One of the two patients receiving systemic administration of Kineret showed mild efficacy. A total of 21 IA Kineret injections were performed on nine patients. Only 2/5 patients receiving IA Kineret injections into small/medium-sized joints showed efficacy and only 2/5 patients receiving IA Kineret injections into large joints (knees, shoulders) showed efficacy – but those patients showing efficacy with large joints injections had >50% improvement.
Conclusion: In this study it was found that patients receiving large joint injections were more likely to show greater efficacy than those receiving small joint injections. Therefore, there seems to be a possible benefit of using Kineret (150–200 mg) in the treatment of OA in large joints and may represent an alternative to IA steroid in those patients in whom steroids may be contraindicated. |
| format | Article |
| id | doaj-art-0b93c759873049f5b44117e09c647f7a |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-0b93c759873049f5b44117e09c647f7a2025-02-03T11:42:56ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012017-01-01121172210.4103/0973-3698.199125Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritisCraig Davis ScovilleJohn Partridge DicksonBackground: Novel treatments for osteoarthritis (OA) are needed for patients not responding to and/or not tolerating conventional treatments. In this prospective study the usefulness of Anakinra (Kineret) in the treatment of OA was evaluated. Methods: Eleven patients with symptomatic OA were treated with Anakinra (Kineret) over a 2–3 month period. Efficacy of response was determined if patients showed >30% improvement in the Western Ontario and McMaster Universities Osteoarthritis Index and/or Australian/Canadian Osteoarthritis Hand Index scoring with treatment. Nine of the 11 patients received Kineret intra-articular (IA) injections and 2/11 patients with erosive polyosteoarthritis received Kineret 100 mg subcutaneous injections daily for 30 days. Results: One of the two patients receiving systemic administration of Kineret showed mild efficacy. A total of 21 IA Kineret injections were performed on nine patients. Only 2/5 patients receiving IA Kineret injections into small/medium-sized joints showed efficacy and only 2/5 patients receiving IA Kineret injections into large joints (knees, shoulders) showed efficacy – but those patients showing efficacy with large joints injections had >50% improvement. Conclusion: In this study it was found that patients receiving large joint injections were more likely to show greater efficacy than those receiving small joint injections. Therefore, there seems to be a possible benefit of using Kineret (150–200 mg) in the treatment of OA in large joints and may represent an alternative to IA steroid in those patients in whom steroids may be contraindicated.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2017;volume=12;issue=1;spage=17;epage=22;aulast=ScovilleAnakinrakinerettreatment of osteoarthritis |
| spellingShingle | Craig Davis Scoville John Partridge Dickson Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis Indian Journal of Rheumatology Anakinra kineret treatment of osteoarthritis |
| title | Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis |
| title_full | Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis |
| title_fullStr | Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis |
| title_full_unstemmed | Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis |
| title_short | Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis |
| title_sort | open label use of anakinra kineret in the treatment of patients with osteoarthritis |
| topic | Anakinra kineret treatment of osteoarthritis |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2017;volume=12;issue=1;spage=17;epage=22;aulast=Scoville |
| work_keys_str_mv | AT craigdavisscoville openlabeluseofanakinrakineretinthetreatmentofpatientswithosteoarthritis AT johnpartridgedickson openlabeluseofanakinrakineretinthetreatmentofpatientswithosteoarthritis |